Zobrazeno 1 - 10
of 20
pro vyhledávání: '"K J, Tack"'
Autor:
K. J. Tack, C. Lell, Zrinka Ivezic-Schoenfeld, F. Obermayr, R. Novak, W. T. Prince, G. H. Talbot
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2087-2094
This study investigated the potential of the novel systemic pleuromutilin antibiotic BC-3781 to treat patients with an acute bacterial skin and skin structure infection (ABSSSI) caused by a Gram-positive pathogen. Patients were randomized to intraven
Publikováno v:
Chemotherapy. 36:70-76
Fifty-eight males and 34 females with nongonococcal urethritis and/or cervicitis were treated to compare the efficacy and safety of 7-day regimens of oral ofloxacin 300 mg twice daily and doxycycline hyclate 100 mg twice daily. Forty-seven patients w
Autor:
Shigeru Kohno, Keizo Yamaguchi, Shinichi Watanabe, Masutaka Furue, Yoshinobu Sumiyama, N. Aoki, Naoki Aikawa, S. Odagiri, K. J. Tack, Yoshihito Niki, R. Croos-Dabrera, T. Ito
Publikováno v:
The Journal of antimicrobial chemotherapy. 60(6)
Objectives: To compare the efficacy and safety of linezolid and vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in Japan. Methods: Patients with nosocomial pneumonia, complicated skin and soft-tissue infe
Publikováno v:
International journal of clinical practice. 54(5)
To compare the efficacy and safety of five-day cefdinir treatment with seven-day loracarbef treatment in patients with acute exacerbations of chronic bronchitis, 586 patients were enrolled in a multicentre, randomised, double-blind trial. Patients re
Publikováno v:
Clinical therapeutics. 21(11)
Cefdinir, an oral cephalosporin active against Streptococcus pyogenes (group A beta-hemolytic streptococci [GABHS]), is also resistant to degradation by most oropharyngeal beta-lactamases. This multicenter, randomized, controlled, double-masked study
Publikováno v:
Antimicrobial agents and chemotherapy. 42(5)
A multicenter, randomized, controlled, investigator-blind study was performed to evaluate the safety and efficacy of oral cefdinir versus oral penicillin V for the treatment of pharyngitis due to group A beta-hemolytic streptococci (GABHS). Patients
Publikováno v:
Clinical therapeutics. 20(2)
Because of increasing resistance to older antimicrobial agents, newer drugs need to be evaluated for the treatment of skin and skin-structure infections (SSSIs). This double-masked, randomized, comparative, multicenter study enrolled patients aged 13
Autor:
W M Scheld, S Savolainen, C Keyserling, P Rivas, K J Tack, Jack M. Gwaltney, A Sydnor, P Schenk, A Leigh
Cefdinir is an extended-spectrum oral cephalosporin that is active against pathogens commonly seen in acute community-acquired bacterial sinusitis (ACABS), including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Two ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba80d848ea0ba40edf34b6e943c74b86
https://europepmc.org/articles/PMC163951/
https://europepmc.org/articles/PMC163951/
Publikováno v:
Archives of pediatricsadolescent medicine. 151(1)
To compare the safety and efficacy of a 5-day regimen of cefdinir with those a conventional 10-day regimen of penicillin V for the treatment of streptococcal pharyngitis in children.Investigator-blind, randomized controlled trial.Primary care, ambula
Publikováno v:
Clinical therapeutics. 18(4)
In this randomized, open-label, dose-comparative study, 18 investigators enrolled 466 patients with acute bronchitis. Patients were randomly assigned to receive either 600 mg of cefdinir once daily (QD) or 300 mg of cefdinir twice daily (BID) for 10